As a result, 10 components with higher degree centrality were determined to be the active ingredients of XPF, and 10 hub genes, including ACE2, HTR1A, HTR2A, AKT1, PKIA, CREB1, BDNF, BCL2, BAX, CASP3, and cAMP were determined as targets of XPF in treating CHD with depression. This evidence concerns the gene BCL2 and depressive disorder.